Risk of second primary malignancy in patients with primary myelofibrosis: A SEER database study.

• DOI: 10.1200/jco.2022.40.16_suppl.e19079
• Publication Date: 2022-06-06T16:55:53Z
• Authors: Utsav Joshi; Adheesh Bhattarai; Suman Gaire; Simrat Gill; Vishakha Agrawal; Uttam Bhetuwal; Peter Kouides; Vijaya Raj Bhatt
• Keywords: Cumulative incidence

e19079 Background: Primary myelofibrosis (PMF) carries a poorer prognosis compared to other BCR-ABL-negative myeloproliferative diseases (MPD), and there is increased risk of early mortality due blast transformation, thrombosis, bleeding complications, progression disease. Prior studies report greater incidence second primary malignancy (SPM) among MPD patients, although the true in PMF has not been elucidated. We performed large database study evaluate SPM patients analyzed effects sociodemographic factors on SPM. Methods: used Surveillance, Epidemiology, End Results (SEER) identify all with histologic diagnosis from 2009 2018. was defined as any subsequent that developed at least 1 year after PMF. Using multiple standardized ratio (SIR) session SEER*Stat software (version 8.3.9), we calculated SIR absolute excess (AER) for entire cohort also stratified based age, sex, race, marital status, receipt chemotherapy, follow-up duration, diagnosis. generated 95% confidence intervals (CI) p-values assuming Poisson distribution observed incidences Results: A total 5,273 were included analysis, which 342 (6.4%) occurred 1.97 (95% CI 1.77-2.18, p<0.05) AER 151.87 per 10,000 population. significantly higher melanoma (SIR 1.96, 1.14-3.14, p<0.05), lymphoma 3.45, 2.31-4.96, leukemia 26.87, 22.69-31.59, observed. There no statistically significant difference chemotherapy. The ≤60 years vs >60 2.34, 1.89-2.86 1.86, 1.65-2.10, p 0.01) diagnosed ≤2009 2.64, 2.26-3.07 1.61, 1.40-1.85, p<0.001). Conclusions: Patients are high developing SPM, especially lymphoma. Data suggests aged decade 2009. impact ruxolitinib, approved 2011, deserves further study. [Table: see text]